drugset / Trial / NCT06568042

Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy

NCT06568042 ↗

Phase 2 Completed 558 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate how safe and how well a treatment works compared to placebo for people with nerve pain that begins in their feet and moves up the leg to just below the knee. Participation may last up to 30 weeks including screening.

Timeline

Start
2024-08-22
Primary completion
2026-01-12
Completion
2026-04-15

Drugs

EvaluationDrugModalityDoseRoute
Subject LY3848575 Unknown — Subcutaneous